Inform Genomics Inc.
Predicting side effects of specific drug regimens
This article was originally published in Start Up
Executive Summary
While other personalized medicine companies tend to focus on selecting the most effective therapeutic drug, say for cancer, Inform Genomics Inc.’s focus with its lead product is to identify patients who have a genetic predisposition to specific side effects from cancer treatments. The company is looking across vast networks of genes to pinpoint characteristics that spell trouble for a patient. Each genetic profile is unique to the risks associated with a specific drug regimen: a patient’s profile may raise a red flag for severe side effects associated with one regimen, but may show that another regimen may be relatively safe.